Sara has nearly 20 years of banking and institutional investment experience. Prior to joining Avoro Ventures in February 2021, Sara was a Partner at New Enterprise Associates (NEA) focused on private biopharma investments. Over her 12 years at NEA, Sara invested across six funds totaling greater than $15 billion in committed capital. She played a key diligence and management role in 25 investments, from which there have been 10 IPOs and 9 acquisitions with upfront payments exceeding $16 billion. Prior to joining NEA, Sara worked in investment banking at both Merrill Lynch and Morgan Stanley. Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University. Sara currently serves on the board of Vanqua Bio Inc., a biotechnology company focused on developing novel therapies for Parkinson’s disease and other neurological disorders, and as a board observer for Scribe Therapeutics, a private molecular engineering company developing CRISPR-based in vivo therapies.